Switzerland· 68239001
Oxlumo 94.5 mg / 0.5 ml, Injektionslösung
A lumasiran product containing lumasiranum, registered in Switzerland by Alnylam Switzerland GmbH and dispensed under Swissmedic category B. The same ATC class is registered in 12 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Lumasiran is registered in 12 of 19 countries.
Countries holding a registration under ATC A16AX18 (lumasiran), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 8 of them publish a price we can compare per daily dose
Lumasiran · ATC A16AX18
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Swissmedic (Switzerland)- Active substance
- lumasiranum
- Manufacturer
- Alnylam Switzerland GmbH
- Country
- Switzerland (CH)
- ATC code
- A16AX18
- ATC class
- Lumasiran
- Defined daily dose
- 2.3 mg, P
- Swissmedic category
- B
- Reimbursed
- No
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Lumasiran in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainOXLUMO 94,5 mg/0,5 ml SOLUCION INYECTABLEAlnylam Netherlands B.V.
- IcelandOxlumoAlnylam Netherlands B.V.
- PolandOxlumoAlnylam Netherlands B.V.
- SwedenOxlumo 94,5 mg/0,5 ml Injektionsvätska, lösningAlnylam Netherlands B.V.
- CanadaOXLUMOALNYLAM NETHERLANDS B.V.
- FranceOXLUMO 94,5 mg/0,5mL, solution injectableALNYLAM NETHERLANDS (PAYS-BAS)
- United KingdomOxlumo 94.5mg/0.5ml solution for injection vialsAlnylam UK Ltd
- NetherlandsOxlumo 189 mg/ml, oplossing voor injectieAlnylam Netherlands B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Oxlumo
- Liechtenstein · Oxlumo
- Norway · Oxlumo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/3ae52eb9-7915-4d21-8355-47efc70d6dac GET /v1/drugs/3ae52eb9-7915-4d21-8355-47efc70d6dac?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "swissmedic_auth",
"heilmittelcode": "Transplantat: Gentherapieprodukt"
}See everything about lumasiran.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.